All-cause mortality and medication risk factors in schizophrenia: A prospective cohort study

Journal of Clinical Psychopharmacology

Volumn 32, Issue 1, 2012, Pages 31-35

  Tenback, Diederik ^a,b   Pijl, Bram ^a   Smeets, Hugo ^b   Os, Jim Van ^c   Harten, Peter Van ^a,c  

^a GGZ Centraal   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

clinical pharmacology; cohort studies; epidemiology; mortality; schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; FEMALE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CAUSE OF DEATH; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SCHIZOPHRENIA;

EID: 84855357435     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31823f3c43     Document Type: Article

References (36)

1. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology. Schizophr Res. 2008;102:1-18.
2. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131. (Pubitemid 47529346)
3. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620-627.
4. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13. (Pubitemid 46762118)
5. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res. 2009;113:1-11.
6. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry. 2001;158:360-369. (Pubitemid 32205190)
7. Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry. 2005;66:1130-1133. (Pubitemid 41442279)
8. Tenback DE, van Harten PN, Slooff CJ, et al. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol (Oxford, England). 2009;24:1031-1035.
9. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-27.
10. Chong SA, Tay JA, Subramaniam M, et al. Mortality rates among patients with schizophrenia and tardive dyskinesia. J Clin Psychopharmacol. 2009;29:5-8.
11. Ballesteros J, Gonzalez-Pinto A, Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J Clin Psychopharmacol. 2000;20:188-194. (Pubitemid 30202361)
12. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66:1116-1121. (Pubitemid 41442277)
13. Ronning M, Blix HS, Harbo BT, et al. Different versions of the anatomical therapeutic chemical classification system and the defined daily doseVare drug utilisation data comparable? Eur J Clin Pharmacol. 2000;56:723-727. (Pubitemid 32204496)
14. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" Clinical features and conceptualization. Schizophr Res. 2009;110:1-23.
15. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2008;69:472-479. (Pubitemid 351549403)
16. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
17. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212-217.
18. Barnes M, Lawford BR, Burton SC, et al. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust N Z J Psychiatry. 2006;40:575-580. (Pubitemid 43805628)
19. Matthews AM, Wilson VB, Mitchell SH. The role of antipsychotics in smoking and smoking cessation. CNS Drugs. 2011;25:299-315.
20. Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. Smoking and schizophrenia. Psychiatr Danub. 2009;21:371-375.
21. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425. (Pubitemid 38326094)
22. Yagi G, Takamiya M, Kanba S, et al. Mortality rate of schizophrenic patients with tardive dyskinesia during 10 years: a controlled study. Keio J Med. 1989;38:70-72.
23. Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand. 1987;75:74-77. (Pubitemid 17019556)
24. Hollis J, Touyz S, Grayson D, et al. Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001. Aust N Z J Psychiatry. 2006;40:981-986. (Pubitemid 44575016)
25. Enger C, Weatherby L, Reynolds RF, et al. Serious cardiovascular events and mortality among patients with schizophrenia. J Nervous Mental Dis. 2004;192:19-27. (Pubitemid 38101693)
26. Baandrup L, Gasse C, Jensen VD, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry. 2010;71:103-108.
27. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005;118(suppl 2):15S-22S.
28. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303:1401-1409.
29. Bitter R, Demler TL, Opler L. Safety evaluation of the concomitant use of clozapine and benzodiazepines: a retrospective, cross-sectional chart review. J Psychiatr Pract. 2008;14:265-270.
30. Haukka J, Tiihonen J, Harkanen T, et al. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol Drug Saf. 2008;17:686-696.
31. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr Res. 2010;117:68-74.
32. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101:295-303.
33. Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687-700. (Pubitemid 46816822)
34. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010;122:1-23.
35. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med. 2000;342:1907-1909.
36. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health. 1996;86:726-728. (Pubitemid 26145488)